INMB · All filings · Read this filing
What changed 10-Q
Item 5. Other Information
2026-08-06 compared with 2026-05-07 · 3 added, 1 removed, 25 unchanged (14% of the section changed)
Other Information
−Removed: During the fiscal quarter ended March 31, 2026, none of the Company’s directors or officers adopted , modified , or terminated a Rule 10b5-1 trading arrangement, or a non-Rule 10b5-1 trading arrangement, in each case as defined in Item 408 of Regulation S-K.
+Added: During the fiscal quarter ended June 30, 2026, none of the Company’s directors or officers adopted , modified , or terminated a Rule 10b5-1 trading arrangement, or a non-Rule 10b5-1 trading arrangement, in each case as defined in Item 408 of Regulation S-K.
Rule 13a-14(a)/ 15d-14(a) Certification of Chief Executive Officer*
15 unchanged sentences
INmune Bio Inc.
+Added: August 6, 2026
/s/ David Moss
1 unchanged sentence
(Principal Executive Officer)
+Added: August 6, 2026
/s/ Cory Ellspermann
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.